Cidara Therapeutics/CDTX

0.44%
-
1D1W1MYTD1YMAX

About Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Ticker

CDTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeffrey Stein

Employees

69

Headquarters

San diego, United States

CDTX Metrics

BasicAdvanced
US$51M
Market cap
-
P/E ratio
-US$8.07
EPS
0.98
Beta
-
Dividend rate
US$51M
0.98201
US$29.60
US$10.00
64K
0.716
0.605
-54.24%
-805.26%
-218.59%
1.103
-44.42%
-84.29%
74.31%

What the Analysts think about CDTX

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
621.58% upside
High US$140.00
Low US$25.00
US$11.26
Current price
US$81.25
Average price target

CDTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-122.61% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$8.4M
-52%
Net income
-US$10M
83.93%
Profit margin
-122.61%
283.16%

CDTX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1,040%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-US$2.80
-US$1.80
-US$0.80
-US$2.28
-
Expected
-US$2.60
-US$3.25
-US$2.07
-US$0.20
-US$4.10
Surprise
7.69%
-44.62%
-61.29%
1,040%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cidara Therapeutics stock?

Cidara Therapeutics (CDTX) has a market cap of $51M as of May 20, 2024.

What is the P/E ratio for Cidara Therapeutics stock?

The price to earnings (P/E) ratio for Cidara Therapeutics (CDTX) stock is 0 as of May 20, 2024.

Does Cidara Therapeutics stock pay dividends?

No, Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Cidara Therapeutics dividend payment date?

Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Cidara Therapeutics?

Cidara Therapeutics (CDTX) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Cidara Therapeutics stock price target?

The target price for Cidara Therapeutics (CDTX) stock is $81.25, which is 621.58% above the current price of $11.26. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cidara Therapeutics stock

Buy or sell Cidara Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing